Evidence map›Paper›PMID 24081158›Full record

Trial reportThe Journal of physiology2013

Tendon and skeletal muscle matrix gene expression and functional responses to immobilisation and rehabilitation in young males: effect of growth hormone administration.

A P Boesen, K Dideriksen, C Couppé, S P Magnusson, P Schjerling, M Boesen, M Kjaer, H Langberg

3 registry-linked trialsOpen access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in The Journal of physiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02420353 phase2completednot on this mapstarted 2015, after this paper: background citation

Evaluation of Recombinant Growth Hormone Therapy to Prevent Muscle Atrophy in Patients With Anterior Cruciate Ligament Tears

TypeinterventionalSponsorUniversity of MichiganRan2015 to 2018Enrolled20ConditionsRupture of Anterior Cruciate LigamentArmsSomatropin, Placebo
NCT02597660 phase2withdrawnnot on this mapstarted 2020, after this paper: background citation

A Double-Blind Placebo-Controlled Study to Evaluate the Efficacy of Somatropin in the Treatment of Patellar Tendinopathy

TypeinterventionalSponsorHospital for Special Surgery, New YorkRan2020 to 2020Enrolled0ConditionsTendinopathyArmsSomatropin, Bacteriostatic saline, Progressive exercise program, Patellar tendon biopsy
NCT07036003 phase1 / phase2active not recruitingnot on this mapstarted 2025, after this paper: background citation

Recombinant Human Growth Hormone (rHGH) for Knee Osteoarthritis (KORR): a Pilot, Randomized Placebo-controlled Trial

TypeinterventionalSponsorDr. David WassersteinRan2025 to 2029Enrolled34ConditionsKnee Osteoarthritis (Knee OA), Knee Osteoarthritis (OA)ArmsSomatropin (recombinant human growth hormone), bacteriostatic saline placebo
3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

A P BoesenA. P. Boesen: Institute of Sports Medicine, Department of Orthopaedic Surgery M, Bispebjerg Hospital, Bispebjerg Bakke 23, DK-2400 Copenhagen, Denmark. boesenanders@hotmail.com.
K Dideriksen
C Couppé
S P Magnusson
P Schjerling
M Boesen
M Kjaer
H Langberg
University of Copenhagen · DKBispebjerg Hospital · DKFrederiksberg Hospital · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We examined the effect of growth hormone (GH) on connective tissue of tendon and skeletal muscle during immobilisation and re-training in humans. Young men (20-30 years; n = 20) were randomly assigned to daily recombinant human GH (rhGH) (33-50 μg kg(-1) day(-1)) or placebo (Plc), and had one leg immobilised for 2 weeks, followed by 6 weeks of strength training. The cross-sectional area (CSA), maximal muscle strength (maximal voluntary contraction, MVC) and biomechanical properties of the quadriceps muscle and patellar tendon were determined. Muscle and tendon biopsies were analysed for mRNA of collagen (COL1A1/3A1), insulin-like growth factors (IGF-1Ea/Ec), lysyl oxidase (LOX), matrix metalloproteases (MMP-2 and MMP-9), decorin and tenascin-C. Fibril morphology was analysed by transmission electron microscopy (TEM) to detect changes in the fibril diameter distribution. In muscle, CSA and MVC declined with immobilisation and recovered with rehabilitation similarly in both groups. Likewise, both groups showed increased IGF-1Ea/Ec and COL1A1/3A1 expression in muscle during re-training after immobilisation compared with baseline, and the increase was more pronounced when subjects received GH. The tendon CSA did not change during immobilisation, but increased in both groups during 6 weeks of rehabilitation (∼14%). A decline in tendon stiffness after immobilisation was observed only in the Plc group, and an increase during 6 weeks of rehabilitation was observed only in the GH group. IGF-1Ea and COL1A1/3A1 mRNA increased with immobilisation in the GH group only, and LOX mRNA was higher in the GH group than in the Plc group after immobilisation. Both groups showed an increase in MMP-2 with immobilisation, whereas no changes in MMP-9, decorin and tenascin-C were observed. The tendon fibril diameter distribution remained unchanged in both groups. In conclusion, GH stimulates collagen expression in both skeletal muscle and tendon, abolishes the normal inactivity-related decline in tendon stiffness and LOX, and results in increased tendon CSA and stiffness during rehabilitation. GH has a matrix-stabilising effect during periods of inactivity and rehabilitation in humans.

Indexed as

AdultCollagen Type ICollagen Type I, alpha 1 ChainCollagen Type IIIDouble-Blind MethodExerciseGene ExpressionHuman Growth HormoneHumansImmobilizationInsulin-Like Growth Factor ILower ExtremityMaleMatrix Metalloproteinase 2Microscopy, Electron, TransmissionMuscle, SkeletalCOL3A1 protein, humanCollagen Type ICollagen Type I, alpha 1 ChainCollagen Type IIIHuman Growth HormoneIGF1 protein, humanInsulin-Like Growth Factor IMatrix Metalloproteinase 2MMP2 protein, humanProtein-Lysine 6-OxidaseRecombinant Proteins

Identifiers

PMID24081158
PMCPMC3872768
OpenAlexW2152702805

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.